Novel Quinolinylaminoisoquinoline Bioisosteres of Sorafenib as Selective RAF1 Kinase Inhibitors: Design, Synthesis, and Antiproliferative Activity against Melanoma Cell Line

DOI Web Site Web Site PubMed 2 References
  • Cho Hye Jung
    Chemical Kinomics Research Center, Korea Institute of Science and Technology Department of Chemistry, Hanyang University
  • El-Gamal Mohammed Ibrahim
    Center for Biomaterials, Korea Institute of Science and Technology Department of Biomolecular Science, University of Science and Technology Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura
  • Oh Chang-Hyun
    Center for Biomaterials, Korea Institute of Science and Technology Department of Biomolecular Science, University of Science and Technology
  • Lee So Ha
    Chemical Kinomics Research Center, Korea Institute of Science and Technology
  • Sim Taebo
    Chemical Kinomics Research Center, Korea Institute of Science and Technology
  • Kim Garam
    College of Pharmacy, Chosun University
  • Choi Hong Seok
    College of Pharmacy, Chosun University
  • Choi Jung Hoon
    Department of Chemistry, Hanyang University
  • Yoo Kyung Ho
    Chemical Kinomics Research Center, Korea Institute of Science and Technology

Search this article

Abstract

Design and synthesis of a new series of quinolinylaminoisoquinoline derivatives as conformationally restricted bioisosteres of Sorafenib are described. Their in vitro antiproliferative activity against A375P melanoma cell line was tested. Compounds 1b, 1d, 1g, and 1j showed the highest potency against A375P cell line with IC50 values in sub-micromolar scale. In addition, compound 1d exerted high selectivity towards RAF1 serine/threonine kinase with 96.47% inhibition at 10 µM, and IC50 of 0.96 µM. This compound can possess antiproliferative activity against melanoma cells through inhibition of RAF1 kinase.

Journal

References(2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top